Healthcare & life sciences
Premium virtual data room solutions that help protect sensitive clinical data, navigate regulatory requirements and ensure IP protection across healthcare M&A, capital raising, exits and licensing deals.
Trusted by healthcare & life sciences dealmakers
Pharmaceutical and biotech companies, healthcare providers and life sciences advisors depend on Sterling to protect sensitive clinical data, IP and patient information throughout divestitures, capital raises and licensing deals.
AnaCardio, the Sweden-based clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, used Sterling Technology for three financing rounds, raising SEK
Lima Corporate, the Italy-based manufacturer of prosthetics, and its advisors Goldman Sachs, Mediobanca and Morgan Stanley, used Sterling Technology for its sale to Enovis from EQT for
Verona Pharma, the US-listed respiratory diseases biopharmaceutical company, and its advisor Centerview Partners, used Sterling Technology for its acquisition by Merck & Co for
CareMax, the US-based medical center operator, and its advisors Alvarez & Marsal and Piper Sandler, used Sterling Technology for the sale of its operating clinics to ClareMedica Health Partners for
Astellas Pharma, the Japan-listed pharmaceutical company, used Sterling Technology for the sale of DIFICLIR, used to treat Clostridium difficile, to Switzerland-based Tillotts Pharma for
Healthcare and life-sciences deals involve sharing sensitive clinical data, intellectual property, and regulatory submissions – each requiring secure, traceable handling
Sterling’s VDR platform protects confidentiality while keeping transactions on schedule. Our automated translation feature accelerates cross-border due diligence, an advanced redaction tool protects sensitive information and maintains compliance with data privacy regulations, while permission-based access ensures that only qualified reviewers see critical material. Detailed audit trails meet the strictest governance standards, and our 24/7 multilingual support ensures uninterrupted progress across time zones. From licensing and fundraises to divestitures and spin-offs, Sterling enables healthcare dealmakers to share data confidently, maintain compliance and complete transactions that unlock value and innovation. Our unique, secure CAD viewer allow bidders to inspect and manipulate 2D and 3D models of molecules without downloads or third-party software.
Maintain regulatory compliance during your process
Secure infrastructure, encrypted storage and detailed access controls protect patient data while enabling necessary due diligence. Sterling's platform meets the highest data security standards, our permission controls restrict patient information access to authorized individuals only, our audit trails document proper handling of protected health information, and our security certifications give compliance officers confidence. Avoid regulatory risk that could derail transactions or impact valuations.
Protect valuable IP and clinical data
Control access to drug candidates, clinical trial results and regulatory submissions with Sterling's sophisticated permission management. Our granular controls let you share Phase 2 results with multiple potential partners while restricting manufacturing processes to serious bidders, our information rights management and watermarking protects sensitive clinical documents, and our instant access revocation ensures departing partners can't retain your IP. Share information with potential partners while maintaining ability to protect assets if negotiations end.
Navigate complex regulatory pathways
Organize FDA submissions, clinical documentation and regulatory correspondence in structured format that helps buyers evaluate regulatory risk. Sterling's folder organization separates regulatory approvals by indication and geography, our bulk upload handles thousands of clinical documents efficiently, and our indexing makes complex regulatory history accessible. Demonstrate regulatory compliance and pathway clarity that gives buyers confidence in your asset and accelerates their approval processes.
Manage parallel licensing and acquisition discussions
Run multiple partnership conversations simultaneously without parties knowing about each other using Sterling's separate data room capability. Our permission architecture creates completely isolated environments for different potential partners, our analytics show you which partners are most engaged with clinical data versus commercial projections, and our Q&A management keeps discussions organized without cross-contamination. Maintain negotiating leverage by having options while protecting sensitive strategic information from competing bidders.
Healthcare & life sciences use cases
Navigate healthcare's unique regulatory and data requirements across divestitures, capital raises, licensing and partnership transactions.
Pharmaceutical licensing
Out-licensing drug candidates requires demonstrating clinical proof-of-concept while protecting manufacturing know-how. Sterling's secure environment lets you run parallel discussions with multiple pharma partners, with separate data rooms ensuring each sees only relevant indication data. Our detailed analytics show which potential partners are most engaged with your clinical results, helping prioritize partnership discussions.
Biotech capital raise
Early-stage life sciences companies raising growth equity or debt financing must demonstrate clinical progress across multiple funding rounds. Sterling's platform evolves with you – from seed rounds sharing early data to Series B rooms with comprehensive clinical results. Our version control ensures investors always see current information, while our free deal prep means you only pay once each funding round goes live.
Hospital or clinic divestiture
Healthcare facility sales require demonstrating patient volumes while maintaining regulatory compliance. Sterling's secure platform protects patient data with bank-grade encryption. Our permission controls separate clinical quality data from financial performance, letting you manage what different buyer types see. When managing sensitive physician relationships, our Q&A keeps stakeholder communications organized and confidential.
Medical device company sale
Device manufacturer exits demand demonstrating regulatory positioning while protecting design specifications. Sterling's document organization separates FDA approvals and clinical evidence (shareable widely) from design files and manufacturing processes (restricted to serious buyers). Our watermarking, inforrmation rights management and view-only controls protect technical IP, while our download tracking shows exactly what each strategic acquirer accessed.
Prep your deal fast and stay compliant with built-in document review and approval.
Granular information rights management to keep you in control of what you share with bidders — and revoke access immediately.
Simple or advanced Q&A workflows that align to your deal process.
.svg)
Our automated redaction tool operates across the whole VDR, saving valuable time and costs preparing sensitive information for external review.
Built-in, automatic, side-by-side translation of VDR content between 300 language pairs keeps your cross-border deals moving.
Real-time dashboards and reports to keep you informed of deal activity and provide strategic intelligence on bidder behavior.
Sterling's unique, built-in AI engine embeds capabilities such as document classification and organization, gap analysis, anomaly detection and document-level Q&A intelligence into the VDR. Launch deals faster – cutting data room prep time from weeks to days – while allowing bidders and investors to complete due diligence more quickly, to close your transaction.
Prep your deal fast and stay compliant with built-in document review and approval.
Granular information rights management to keep you in control of what you share with bidders — and revoke access immediately.
Simple or advanced Q&A workflows that align to your deal process.
Our automated redaction tool operates across the whole VDR, saving valuable time and costs preparing sensitive information for external review.
Built-in, automatic, side-by-side translation of VDR content between 300 language pairs keeps your cross-border deals moving.
Real-time dashboards and reports to keep you informed of deal activity and provide strategic intelligence on bidder behavior.
Sterling's unique, built-in AI engine embeds capabilities such as document classification and organization, gap analysis, anomaly detection and document-level Q&A intelligence into the VDR. Launch deals faster – cutting data room prep time from weeks to days – while allowing bidders and investors to complete due diligence more quickly, to close your transaction.
High-touch 24/7 multilingual support for healthcare & life sciences deals
In healthcare & life sciences, transactions are demanding and time-sensitive. Sterling’s differentiator is the depth of support we provide on every project, from the earliest planning stages through detailed due diligence and final closing.
We work with you to design an intuitive data room structure, set up folders and indexes, upload and categorise documents, define user groups and permissions, configure Q&A routes and approvals, create bidder and adviser teams, and ensure all participants are properly invited and trained.
Our multilingual customer service team sits in-house, operating 24/7/365 via phone and email. Every project has a dedicated deal manager overseeing activity, and, unlike others, your “out-of-hours” support is never handed to a generic call centre.
As you approach completion, we can supply encrypted deal archives and comfort letters quickly, wherever they are needed, so healthcare & life sciences signings and closings can move ahead seamlessly.
Navigating Digital Deals in Life Sciences Part 5 | Deal Structure, Terms and Series Conclusions
Welcome to the fifth and final episode in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions...
Navigating Digital Deals in Life Sciences Part 5 | Deal Structure, Terms and Series Conclusions
by Philip Whitchelo
Welcome to the fifth and final episode in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions...
Learn more ->
Navigating Digital Deals in Life Sciences Part 4 | Due Diligence
Welcome to the fourth of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions...
Navigating Digital Deals in Life Sciences Part 4 | Due Diligence
by Philip Whitchelo
Welcome to the fourth of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions...
Learn more ->
Navigating Digital Deals in Life Sciences Part 3 | Defining & Valuing the Asset
Welcome to the third of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions...
Navigating Digital Deals in Life Sciences Part 3 | Defining & Valuing the Asset
by Philip Whitchelo
Welcome to the third of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions...
Learn more ->
